Compare TREE & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | IVVD |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.1M | 437.1M |
| IPO Year | 2008 | 2021 |
| Metric | TREE | IVVD |
|---|---|---|
| Price | $44.40 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $71.25 | $8.75 |
| AVG Volume (30 Days) | 282.9K | ★ 5.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 443.31 | 79.02 |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,117,324,000.00 | $53,426,000.00 |
| Revenue This Year | $19.03 | $61.57 |
| Revenue Next Year | $7.07 | $41.42 |
| P/E Ratio | $37.76 | ★ N/A |
| Revenue Growth | 24.12 | ★ 110.47 |
| 52 Week Low | $32.65 | $0.49 |
| 52 Week High | $77.35 | $3.07 |
| Indicator | TREE | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 32.38 |
| Support Level | $43.36 | N/A |
| Resistance Level | $50.99 | $1.01 |
| Average True Range (ATR) | 2.00 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.48 | 0.88 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.